Pharmaceutical Examiners Report - appears to be in relation to Feiba. Noted that this product has been available on a named-patient basis for nine years for the treatment of haemophilia in patients producing inhibitors to Factor VIII. The application for a product licence was received in September 1981 and was found to be inadequate in a number of respects relating to quality. Information on manufacturing and data was lacking. Additional data on heat treatment was discussed and it was noted that the possible transmission of AIDS in Factor vIII concentrates has prompted the DHSS to reuqest that all licence holders for Factor VIII should vary their process to include a validated heat treatment stage.